July 4th 2023
Christian Marth, MD, PhD, reviews the adverse effects of pembrolizumab and lenvatinib in the treatment of endometrial cancer, as well as the patient experience with these treatments.
Bradley J. Monk, MD, FACS, FACOG, and Christian Marth, MD, PhD, share treatment approaches to patients with endometrial cancer with a low response rate to chemotherapy, highlighting a biomarker-based approach.
June 27th 2023
Experts discuss the possibility to avoid use of chemotherapy by using immunotherapy.
Christian Marth, MD, PhD, and Bradley J. Monk, MD, FACS, FACOG, discuss data from the NRG GY018 and RUBY trials regarding the use of immunotherapies for the treatment of endometrial cancer.
June 20th 2023
Bradley J. Monk, MD, FACS, FACOG, reviews the available chemotherapy options for treating advanced and recurrent endometrial cancer, as well as compares notes with Christian Marth, MD, PhD, on his clinical experience.
Christian Marth, MD, PhD, discusses the prevalence of endometrial cancer, as well as the steps that lead to diagnosis.
November 17th 2022
The panel closes their discussion by highlighting their favorite news or update from recent conferences, including ESMO 2022.
Dr Shannon Westin explains the data on treatment of rare tumors in ovarian cancer and why biomarker testing is essential.
November 10th 2022
A key opinion leader reviews data on novel investigational agents for recurrent ovarian cancer.
Drs Coleman and Westin continue the discussion of antibody-drug conjugates for treatment of ovarian cancer.
November 4th 2022
Dr Michael Birrer highlights updated data on antibody-drug conjugates in ovarian cancer treatment.
Dr Shannon Westin shares if and when she could justify withholding a PARP inhibitor from a patient with HRD-positive ovarian cancer.
October 27th 2022
Experts discuss the best approach to treating patients with ovarian cancer who are resistant to PARP inhibitors.
A look at the maintenance treatment strategies for advanced or metastatic ovarian cancer.
October 20th 2022
Michael J. Birrer, MD, PhD, explains the reasoning for combining PARP inhibitors with immunotherapy in ovarian cancer treatment, highlighting ongoing trials.
Robert L. Coleman, MD, FACOG, FACS, describes data updates from the PRIMA trial investigating PARP inhibition in HRD-negative ovarian cancer populations.
October 17th 2022
Dr Michael Birrer reviews data from the PAOLA-1 trial investigating bevacizumab combination therapy for frontline maintenance therapy in advanced ovarian cancer.
Bradley J. Monk, MD, FACOG, FACS, generates a discussion on the use of PARP inhibitors in ovarian cancer treatment.
October 6th 2022
Shannon N. Westin, MD, MPH, FACOG, explains the study design and outcomes of the SOLO-3 trial.
Dr Robert Coleman reviews data from the ARIEL-4 trial on rucaparib in recurrent ovarian cancer, sparking a discussion on PARP inhibitor use.